Phase III testing for ED drug delayed
August 30, 2007
PTN0.65, -1.08, -62.5%) said that after a review of Phase I and Phase II clinical data, the Food and Drug Administration has expressed concerns that the drug candidate, known as bremelanotide, might raise blood pressure in certain patients.
Accordingly, the agency has questioned its benefit as a first-line therapy, suggesting it may be better suited as a therapy for men who have not responded well to other erectile-dysfunction medications, such as Viagra, Cialis or Levitra.
King and Palatin said they plan to review the FDA’s suggestions in order to determine how best to proceed with the program. End of Story
Posted by toshko under Viagra News |